Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1749)	9/28/2000 1:25:56 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

On a quite different issue, note the forthcoming Rule 10b5-1, which relates to insider sales, and which is part of a broader change that will be effective in about a month. sec.gov Currently, an insider can't sell if he/she is in possession of material non-public information. What this means (and this is particularly relevant to biotech) is that if you do see insider selling at a reputable company, it means there is likely no significant adverse information that just hasn't yet been disclosed. Thus (paradoxically and quite differently from the rest of the world) I'm generally reassured if I see a steady stream of (small relative to holdings) insider sales. What this new 10b5-1 rule will allow for the first time is for insider selling according to a pre-arranged plan. Thus an insider might arrange to sell some number of shares each month provided the price meets some predetermined condition. This will make insider's lives much easier, given that for many companies there is only a very small window where they can currently sell, and that only if there is no significant undisclosed news (such as pending M&A activity). Unfortunately, the rules don't seem to require that these sales be flagged as done pursuant to this new rule, and so unless companies or insiders voluntarily do this (which is certainly possible), my reassurance on seeing an insider sale will be a thing of the past. Peter P.S. Note there have recently been some fairly significant sales by SEPR insiders. I think this is likely just some reasonable diversification - something any sensible financial advisor would suggest to the individuals after the large run-up the stock has enjoyed over the last few years.

To: Biomaven who wrote (1749)	9/28/2000 8:52:00 PM
From: Spekulatius	Read Replies (1) \| Respond to of 52153

I have been in and out SUPG as well and do not hold a position either. Right now, they appear to be a better buy than MOGN, IMHO. SUPG certainly has a hype element but more disturbing to me is that Joe Rubinfeld has lost key people for the clinical trials. This may have to do with the fact that Joe seems to run a family business (his wife is heads the HR) and has a huge ego. The Rubitecan trials are however high powered and if they show a significant clinical, benefit this drug could become a blockbuster, due to its mild side effect profile.